Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations

Iacopo Petrini,1 Giuseppe Giaccone2 1Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 2Weill-Cornell Medicine, Meyer Cancer Center, New York, NY, USACorrespondence: Giuseppe Giaccone, Weill-Cornell Medicine, Meyer C...

Full description

Bibliographic Details
Main Authors:	Petrini I, Giaccone G
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-10-01
Series:	OncoTargets and Therapy
Subjects:	amivantamab exon 20 insertion of egfr nsclc
Online Access:	https://www.dovepress.com/amivantamab-in-the-treatment-of-metastatic-nsclc-patient-selection-and-peer-reviewed-fulltext-article-OTT

Similar Items

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
by: Vishal Shah, et al.
Published: (2023-03-01)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
by: Zhang SS, et al.
Published: (2021-07-01)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
by: Arnold A, et al.
Published: (2023-07-01)

Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-09-01)

Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art
by: Federico Pio Fabrizio, et al.
Published: (2024-03-01)

Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report
by: Jaemin Kim, BS, et al.
Published: (2023-12-01)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
by: Arsela Prelaj, et al.
Published: (2022-06-01)

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating <i>EGFR</i> Exon 20 Insertion Mutations
by: Petros Christopoulos, et al.
Published: (2023-11-01)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
by: Samy Chelabi, et al.
Published: (2021-10-01)

Amivantamab: A narrative drug review
by: Anupa John, et al.
Published: (2023-01-01)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
by: Timothée Olivier, et al.
Published: (2022-09-01)

Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer  Patients with EGFR/MET Gene Abnormalities: A Single Center’s Experience
by: Jingjing WANG, et al.
Published: (2022-07-01)

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets
by: Santiago Viteri, et al.
Published: (2023-02-01)

Severe scalp ulcerations and granulomata during treatment with amivantamab
by: Jingjia J Zhou, et al.
Published: (2024-03-01)

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
by: Giulio Metro, et al.
Published: (2022-07-01)

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
by: Chao Shi, et al.
Published: (2022-09-01)

Bioanalytical method development and validation for quantification of amivantamab in rat plasma by LC-MS/MS
by: Pridhvi Krishna Gaddey, et al.
Published: (2024-04-01)

Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions
by: Ping Yue, et al.
Published: (2024-03-01)

The development of amivantamab for the treatment of non-small cell lung cancer
by: Danielle Brazel, et al.
Published: (2023-10-01)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
by: Waleed Kian, et al.
Published: (2022-09-01)

Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia
by: Karina J. Cancel-Artau, MD, et al.
Published: (2024-03-01)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
by: Yurong Wang, et al.
Published: (2021-11-01)

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
by: Yue Zheng, et al.
Published: (2023-11-01)

Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review
by: Xiao Zhang, et al.
Published: (2022-08-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
by: Hai‐Yan Tu, et al.
Published: (2023-08-01)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
by: Xuesong Chen, et al.
Published: (2023-02-01)

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
by: Oliver Illini, et al.
Published: (2024-04-01)

Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
by: Shun Matsuura, et al.
Published: (2020-01-01)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021-03-01)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
by: YanRu Qin, et al.
Published: (2020-08-01)

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
by: Binyang Pan, et al.
Published: (2023-11-01)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2021-03-01)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
by: Sai-Hong Ignatius Ou, MD, et al.
Published: (2023-10-01)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
by: James Chih-Hsin Yang, et al.
Published: (2022-04-01)

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
by: Maximilian J. Hochmair, et al.
Published: (2024-01-01)

The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms
by: Taishu Wang, et al.
Published: (2018-07-01)

Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
by: Xue YANG, et al.
Published: (2022-05-01)

<i>EGFR</i> Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
by: Laura Pacini, et al.
Published: (2022-01-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
by: Seigo Minami, et al.
Published: (2019-02-01)